SHP2 Inhibitors: Progress and Perspectives in 2024
In 2024, SHP2 inhibitors (SHP2i) remain at the forefront of drug discovery, particularly in the realm of oncology. While there are some perspectives suggesting that the emphasis on SHP2 may indicate a disproportionate preference for well-established targets, current developments underscore…